FDA advisers narrowly back easing compounding limits on BPC-157 and TB-500
An outside advisory panel voted in favor of adding several injectable peptides to the list of substances pharmacies may compound. The FDA has not announced a final decision.
Outside health advisers to the U.S. Food and Drug Administration narrowly voted in late July to recommend removing restrictions that keep pharmacies from compounding certain injectable peptides, including BPC-157, TB-500 and KPV, according to CP24 reporting published July 30.
The vote is advisory. We have not found a final FDA decision, and none of these peptides is an approved drug. The agency had scheduled the advisory committee to consider BPC-157 at a July 23 meeting after it moved the peptide off its Category 2 list in April.
The same reporting quotes Canadian experts cautioning that evidence for most injectable peptides is thin, and a 2025 systematic review found that 35 of 36 BPC-157 studies it identified were preclinical.
Sources
- CP24: peptides are rising in popularity, but experts warn few have benefits (Jul 30, 2026)
- Goodwin: FDA signals potentially evolving stance toward compounding of certain peptides
- PubMed 40756949: BPC-157 systematic review
Related evidence
Cited Peptides summarizes published reporting and research for education. It is not medical or legal advice, and regulatory situations change; check the date above.